Deals this week: Inthera Bioscience, i2 Pharmaceuticals, InventisBio
Swiss-based biopharmaceutical company Inthera Bioscience has completed a series A financing round led by Merck Ventures to raise Sfr10.5m ($10.53m).
Aglaia BioMedical Ventures, Novo Seeds and other private investors also participated in the round.
US-based biotechnology company Sea Lane Biotechnologies has sold its entire antibody and engineered protein technology portfolio to i2 Pharmaceuticals, a biopharmaceutical company also based in the US.
The portfolio includes human antibody libraries, human b-cell derived antibodies and surrobodies, which enable facile creation of bispecific therapeutic agents from arrays of monospecific agents.
Chinese biotechnology company InventisBio has completed a series B venture financing round to raise $19m.
The proceeds will be used to advance the company’s product development through phase one clinical trials.
Rigel Pharmaceuticals intends to raise $40m in gross proceeds through a public offering of shares of its common stock.
The US-based pharmaceutical company intends to use the proceeds for general corporate purposes.